Suppr超能文献

一种碳笼化罗丹明生成硝酰过氧碳酸盐用于光免疫治疗。

A Carbon-Caged Rhodamine Generating Nitrosoperoxycarbonate for Photoimmunotherapy.

机构信息

State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of Chemical Biology, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.

Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.

出版信息

Angew Chem Int Ed Engl. 2024 Jun 21;63(26):e202402949. doi: 10.1002/anie.202402949. Epub 2024 May 24.

Abstract

Photoimmunotherapy is a promising cancer treatment modality. While potent 1-e oxidative species are known to induce immunogenic cell death (ICD), they are also associated with unspecific oxidation and collateral tissue damage. This difficulty may be addressed by post-generation radical reinforcement. Namely, non-oxidative radicals are first generated and subsequently activated into powerful oxidative radicals to induce ICD. Here, we developed a photo-triggered molecular donor (NPCD565) of nitrosoperoxycarbonate (ONOOCO ), the first of its class to our knowledge, and further evaluated its feasibility for immunotherapy. Upon irradiation of NPCD565 by light within a broad spectral region from ultraviolet to red, ONOOCO is released along with a bright rhodamine dye (RD565), whose fluorescence is a reliable and convenient build-in reporter for the localization, kinetics, and dose of ONOOCO generation. Upon photolysis of NPCD565 in 4T1 cells, damage-associated molecular patterns (DAMPs) indicative of ICD were observed and confirmed to exhibit immunogenicity by induced maturation of dendritic cells. In vivo studies with a bilateral tumor-bearing mouse model showcased the potent tumor-killing capability of NPCD565 of the primary tumors and growth suppression of the distant tumors. This work unveils the potent immunogenicity of ONOOCO , and its donor (NPCD565) has broad potential for photo-immunotherapy of cancer.

摘要

光免疫疗法是一种很有前途的癌症治疗方法。虽然已知强 1-e 氧化物种会诱导免疫原性细胞死亡(ICD),但它们也与非特异性氧化和附带的组织损伤有关。这种困难可以通过后代自由基强化来解决。也就是说,首先产生非氧化性自由基,然后将其激活成强大的氧化自由基,以诱导 ICD。在这里,我们开发了一种新型的氮氧自由基供体(NPCD565),它是已知的首个氮氧自由基供体,进一步评估了其在免疫治疗中的可行性。在从紫外线到红光的广泛光谱范围内用光照射 NPCD565 时,会释放出氮氧自由基(ONOOCO ),同时释放出明亮的罗丹明染料(RD565),其荧光是 ONOOCO 生成的位置、动力学和剂量的可靠和方便的内置报告器。在 4T1 细胞中用光解 NPCD565 后,观察到表明 ICD 的损伤相关分子模式(DAMPs),并通过树突状细胞的诱导成熟证实其具有免疫原性。在双侧荷瘤小鼠模型的体内研究中,展示了 NPCD565 对原发性肿瘤的强大杀伤能力和对远处肿瘤的生长抑制作用。这项工作揭示了 ONOOCO 的强大免疫原性,其供体(NPCD565)具有广泛的用于癌症光免疫治疗的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验